[go: up one dir, main page]

NO20042262L - Ikke-neurotoksiske plasminogenaktiverende faktorer til behandling av slag - Google Patents

Ikke-neurotoksiske plasminogenaktiverende faktorer til behandling av slag

Info

Publication number
NO20042262L
NO20042262L NO20042262A NO20042262A NO20042262L NO 20042262 L NO20042262 L NO 20042262L NO 20042262 A NO20042262 A NO 20042262A NO 20042262 A NO20042262 A NO 20042262A NO 20042262 L NO20042262 L NO 20042262L
Authority
NO
Norway
Prior art keywords
stroke
treatment
plasminogen activating
activating factors
activity
Prior art date
Application number
NO20042262A
Other languages
English (en)
Other versions
NO20042262D0 (no
NO329789B1 (no
Inventor
Wolf-Dieter Schleuning
Mariola Sohngen
Wolfgang Sohngen
Robert Medcalf
Original Assignee
Paion Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paion Gmbh filed Critical Paion Gmbh
Publication of NO20042262D0 publication Critical patent/NO20042262D0/no
Publication of NO20042262L publication Critical patent/NO20042262L/no
Publication of NO329789B1 publication Critical patent/NO329789B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
NO20042262A 2001-11-02 2004-06-01 Anvendelse av DSPA alfa 1 for fremstilling av et medikament for terapeutisk behandling av slag hos mennesker NO329789B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10153601A DE10153601A1 (de) 2001-11-02 2001-11-02 DSPA zur Behandlung von Schlaganfall
EP01130006A EP1308166B1 (de) 2001-11-02 2001-12-17 Nicht-neurotoxische Plasminogen Aktivierende Faktoren zur Behandlung von Schlaganfällen
PCT/EP2002/012204 WO2003037363A2 (de) 2001-11-02 2002-10-31 Nicht-neurotoxische plasminogen aktivierende faktoren zur behandlung von schlaganfall

Publications (3)

Publication Number Publication Date
NO20042262D0 NO20042262D0 (no) 2004-06-01
NO20042262L true NO20042262L (no) 2004-06-01
NO329789B1 NO329789B1 (no) 2010-12-20

Family

ID=7704253

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042262A NO329789B1 (no) 2001-11-02 2004-06-01 Anvendelse av DSPA alfa 1 for fremstilling av et medikament for terapeutisk behandling av slag hos mennesker

Country Status (26)

Country Link
US (7) US20050048027A1 (no)
EP (4) EP1308166B1 (no)
JP (2) JP5004407B2 (no)
KR (3) KR20070087248A (no)
CN (2) CN101156948A (no)
AT (3) ATE440614T1 (no)
AU (1) AU2002350660C1 (no)
BR (1) BR0213856A (no)
CA (1) CA2465792C (no)
CY (3) CY1108446T1 (no)
DE (3) DE10153601A1 (no)
DK (3) DK1308166T3 (no)
EA (3) EA010858B1 (no)
ES (3) ES2332576T3 (no)
HR (1) HRP20040383B1 (no)
HU (1) HU230163B1 (no)
IL (1) IL205695A0 (no)
MX (1) MXPA04004155A (no)
NO (1) NO329789B1 (no)
NZ (2) NZ545414A (no)
PL (1) PL208343B1 (no)
PT (3) PT1308166E (no)
SG (1) SG148034A1 (no)
SI (2) SI1441757T1 (no)
WO (1) WO2003037363A2 (no)
ZA (1) ZA200403285B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
AU2003227721A1 (en) * 2003-05-02 2004-11-23 Paion Gmbh Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
US20060135425A1 (en) * 2003-05-02 2006-06-22 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
PL1622639T3 (pl) * 2003-05-02 2013-06-28 Lundbeck H As Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu
KR20060015721A (ko) * 2003-05-05 2006-02-20 파이온 도이치란트 게엠베하 신경보호제로서의 글루타메이트 수용체 길항제
DE10342518A1 (de) * 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
JP2006241109A (ja) * 2005-03-04 2006-09-14 Paion Deutschland Gmbh ヒトＰセレクチンおよびＤＳＰＡα１に対する抗体を含む融合タンパク質
AR068914A1 (es) * 2007-10-18 2009-12-16 Paion Deutschland Gmbh Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia
WO2011107299A2 (en) 2010-04-16 2011-09-09 Paion Deutschland Gmbh Method for the manufacture of recombinant dspa alpha1
ES2583082T3 (es) * 2011-01-05 2016-09-19 Thrombogenics N.V. Variantes de plasminógeno y plasmina
WO2013024074A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
PE20211664A1 (es) * 2018-12-28 2021-08-26 Catalyst Biosciences Inc Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
IL68561A (en) 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
US5244806A (en) * 1985-08-26 1993-09-14 Eli Lilly And Company DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells
DE3643158A1 (de) 1986-04-21 1987-11-19 Boehringer Mannheim Gmbh Gewebs-plasminogen-aktivator(tpa) - derivat und seine herstellung
JPH087179B2 (ja) * 1986-09-27 1996-01-29 日本碍子株式会社 ガスセンサ
WO1988005081A2 (en) * 1986-12-30 1988-07-14 Cetus Corporation Novel plasminogen activator
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same
EP0386240B1 (en) * 1987-10-29 1995-07-19 Yamanouchi Pharmaceutical Co. Ltd. Novel polypeptide compounds
US5094953A (en) * 1988-03-21 1992-03-10 Genentech, Inc. Human tissue plasminogen activator variants
FI100403B (fi) 1988-07-20 1997-11-28 Schering Ag Menetelmä glykosyloitujen tai glykosyloimattomien vampyyrilepakon sylj en plasminogeeniaktivaattoreiden valmistamiseksi
DE3825253A1 (de) 1988-07-25 1990-02-01 Boehringer Mannheim Gmbh T-pa-derivat und seine herstellung
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
JPH0273774A (ja) * 1988-09-09 1990-03-13 Nec Corp ファクシミリ装置
GB8901422D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co New tissue plasminogen activator
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
US5676947A (en) * 1989-02-07 1997-10-14 Boehringer Manneheim Gmbh Method for treating thromboembolic conditions using thrombolytically active proteins
US6008019A (en) 1989-02-13 1999-12-28 Schering Aktiengesellschaft Plasminogen activator from saliva of the vampire bat
DE3904580A1 (de) 1989-02-13 1990-08-16 Schering Ag Neues thrombolytikum
BR9007115A (pt) * 1989-02-13 1991-11-26 Schering Ag Novo trombolitico
DE3917949A1 (de) * 1989-05-30 1991-01-24 Schering Ag Neues thrombolytikum
US5891664A (en) * 1989-04-07 1999-04-06 Cancerforskningsfondet Af 1989 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
DE467932T1 (de) * 1989-04-07 1993-01-14 Cancerforskningsfondet Af 1989, Kopenhagen Plasminogen-aktivator-rezeptor vom urokinasetyp.
JPH0352119A (ja) * 1989-07-19 1991-03-06 Matsushita Electric Ind Co Ltd 光学式記録再生装置
NL8902454A (nl) 1989-10-03 1991-05-01 Stichting Centraal Lab Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
DK0580685T3 (da) 1991-04-16 1996-03-04 Boehringer Mannheim Gmbh Farmaceutisk emballageenhed indeholdende plasminogenaktivatorer til flerfoldig bolusindgift
DE4123845A1 (de) * 1991-07-18 1993-01-21 Boehringer Mannheim Gmbh Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe
US5595736A (en) * 1991-04-22 1997-01-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders
NL9101520A (nl) * 1991-09-09 1993-04-01 Stork Fibron Bv Werkwijze voor het vervaardigen van een eetbaar produkt.
ATE145669T1 (de) 1991-12-16 1996-12-15 Genentech Inc T-pa substitutionsvarianten mit verbesserter fibrinspezifität
RU2183214C2 (ru) * 1992-12-04 2002-06-10 Шеринг Аг Природный и рекомбинантный ингибиторы тромбина, их получение и применение
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
GB9412131D0 (en) * 1994-06-17 1994-08-10 British Bio Technology Thrombolytic composition
DE4423574A1 (de) 1994-07-05 1996-01-11 Boehringer Mannheim Gmbh Nicht-glykosylierte Plasminogenaktivator-Derivate und ihre Verwendung bei erhöhtem Blutungsrisiko
US5827832A (en) 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US5786187A (en) * 1995-09-21 1998-07-28 The Research Foundation Of State University Of New York Method for reducing neuronal degeneration associated with seizure
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke
US20020081294A1 (en) * 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5731186A (en) * 1996-02-05 1998-03-24 Schering Aktiengesellschaft Method for the production of rDSPA α1
US6235947B1 (en) * 1997-04-14 2001-05-22 Takeda Chemical Industries, Ltd. D-mannitol and its preparation
US5830349A (en) * 1996-07-22 1998-11-03 Dana Corporation Flow inverter for filters
JP2001501824A (ja) * 1996-10-01 2001-02-13 ユニバーシティー オブ ジョージア リサーチ ファウンデーション，インコーポレイテッド 昆虫特異的ダニ毒素遺伝子を発現する生物学的昆虫防除剤、方法および組成物
US6008109A (en) * 1997-12-19 1999-12-28 Advanced Micro Devices, Inc. Trench isolation structure having a low K dielectric encapsulated by oxide
KR20010069066A (ko) 2000-01-12 2001-07-23 이종원 저산소 농도하에서 생존이 가능하도록 하는 동물세포의배양방법
DE10008646A1 (de) 2000-02-24 2001-09-13 Kempten Elektroschmelz Gmbh Beschichteter Formkörper aus Siliciumnitrid
GB0025473D0 (en) * 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
US20020089179A1 (en) * 2000-12-30 2002-07-11 Levon Guyumjan Hose coupling apparatus and method
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
PL1622639T3 (pl) 2003-05-02 2013-06-28 Lundbeck H As Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu
AU2003227721A1 (en) 2003-05-02 2004-11-23 Paion Gmbh Intravenous injection of non-neurotoxic plasminogen activators for the treatment of stroke
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
US20060135425A1 (en) * 2003-05-02 2006-06-22 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
KR20060015721A (ko) * 2003-05-05 2006-02-20 파이온 도이치란트 게엠베하 신경보호제로서의 글루타메이트 수용체 길항제
US20050085478A1 (en) 2003-08-22 2005-04-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
DE10342518A1 (de) 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
AR068914A1 (es) * 2007-10-18 2009-12-16 Paion Deutschland Gmbh Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia

Also Published As

Publication number Publication date
EA201000386A1 (ru) 2011-06-30
AU2002350660C1 (en) 2008-10-09
ES2382224T3 (es) 2012-06-06
EP1997510A8 (de) 2011-04-13
US8071091B2 (en) 2011-12-06
NO20042262D0 (no) 2004-06-01
KR20070087248A (ko) 2007-08-27
CY1112957T1 (el) 2016-04-13
ZA200403285B (en) 2005-07-27
ES2332576T3 (es) 2010-02-09
ATE547115T1 (de) 2012-03-15
EP2368567A1 (de) 2011-09-28
DK1441757T3 (da) 2008-11-17
PL369872A1 (en) 2005-05-02
EA200801714A1 (ru) 2008-12-30
US20050048027A1 (en) 2005-03-03
SI1997510T1 (sl) 2012-06-29
CA2465792A1 (en) 2003-05-08
CA2465792C (en) 2014-04-01
KR100816221B1 (ko) 2008-03-24
PT1997510E (pt) 2012-05-21
CY1108446T1 (el) 2014-04-09
HUP0402165A2 (hu) 2005-01-28
EA200400624A1 (ru) 2004-10-28
AU2002350660B2 (en) 2008-04-10
WO2003037363A3 (de) 2003-09-18
EA010858B1 (ru) 2008-12-30
US8119597B2 (en) 2012-02-21
EP1308166B1 (de) 2009-08-26
NZ532903A (en) 2006-10-27
DE50115077D1 (de) 2009-10-08
ATE401910T1 (de) 2008-08-15
EP1441757B1 (de) 2008-07-23
JP2009137983A (ja) 2009-06-25
DK1997510T3 (da) 2012-05-21
MXPA04004155A (es) 2005-03-31
KR20050042234A (ko) 2005-05-06
EP1997510B1 (de) 2012-02-29
CN1592634A (zh) 2005-03-09
EP1997510A1 (de) 2008-12-03
CN100446810C (zh) 2008-12-31
WO2003037363A2 (de) 2003-05-08
PT1441757E (pt) 2008-11-03
HU230163B1 (hu) 2015-09-28
JP2005519025A (ja) 2005-06-30
HK1057328A1 (zh) 2004-04-02
EP1441757A2 (de) 2004-08-04
HRP20040383A2 (en) 2005-08-31
HUP0402165A3 (en) 2010-01-28
CY1109648T1 (el) 2014-08-13
IL205695A0 (en) 2010-11-30
US20090004176A1 (en) 2009-01-01
HRP20040383B1 (hr) 2012-08-31
JP5004407B2 (ja) 2012-08-22
DE10153601A1 (de) 2003-05-22
BR0213856A (pt) 2004-08-31
NZ545414A (en) 2008-09-26
ATE440614T1 (de) 2009-09-15
DK1308166T3 (da) 2009-12-14
PT1308166E (pt) 2009-11-27
SI1441757T1 (sl) 2009-02-28
US20090263373A1 (en) 2009-10-22
SG148034A1 (en) 2008-12-31
CN101156948A (zh) 2008-04-09
PL208343B1 (pl) 2011-04-29
EA013707B1 (ru) 2010-06-30
KR20090128583A (ko) 2009-12-15
US20130039902A1 (en) 2013-02-14
NO329789B1 (no) 2010-12-20
US20140199287A1 (en) 2014-07-17
ES2311070T3 (es) 2009-02-01
US20170051268A1 (en) 2017-02-23
EP1308166A1 (de) 2003-05-07
DE50212548D1 (de) 2008-09-04
US20060142195A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
IL205695A0 (en) Compositions containing dspa alpha 1 for the treatment of stroke
DK1232254T3 (da) Fremgangsmåde til fremstilling af en reversibelt inaktiv syrnet plasminkomponent
ATE356130T1 (de) Inhibitoren von cruzipain und anderen cysteinproteasen
NO910811L (no) Vevsplasminogen-aktivator med zymogeniske- eller fibrinspesifikke egenskaper.
EP0714435A4 (en) PRO-UROKINASE MUTANTS
DK0691858T3 (da) Tokomponent fibrinklæber
NO20021501L (no) Fibrinolyttisk aktivt polypeptid
AU1861588A (en) A method for the determination of the activity of serine proteases or serine protease inhibitors
EP1008348A4 (en) THROMBOLYTIC AGENT
WO2002057246A3 (en) Inhibitors of cruzipain and other cysteine proteases
DK0768892T3 (da) Thrombolytisk præparat
WO2002057248A3 (en) Inhibitors of cruzipain and other cysteine proteases
JPS6434921A (en) Preventive and remedy for thrombosis

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees